Back to search results

Genu-Sparing Whole Brain Radiation for Brain Metastases

This study is looking at a special type of whole brain radiation therapy (WBRT) called Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy. The goal is to see if this treatment can help preserve your thinking and memory skills (cognitive function) if you have brain metastases (cancer that has spread to the brain). Researchers want to find out if avoiding a specific part of the brain called the corpus callosum genu during radiation can prevent the declines in thinking that sometimes happen after WBRT. The study plans to include 40 participants. To join, you must be at least 18 years old, have a solid tumor malignancy, and a good performance status. You also cannot have metastases in the genu area of your brain. The main way success will be measured is by looking at changes in your cognitive function after 4 months. The current status of this study is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 40 participants.
What's involved
You must be scheduled to undergo whole brain radiation therapy. Your cognitive function will be measured at 4 months.
Compensation
Not stated in the trial record.
Follow-up
Your cognitive function will be measured at 4 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03223922

Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

Active, Not Recruiting
NAAges 18+InterventionalTreatment
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
~40 participants
Updated 2026-06-30 on ClinicalTrials.gov
What's tested:whole brain radiation therapy

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of change of cognitive function
Measured over 4 months

Conditions

Brain Metastases

Explore related trials

Metastatic Malignant Neoplasm in the Brain

Where it's being run

2 sites across 2 states
District of Columbia1
Maryland1

Study leadership

  • Kristin Redmond, MD, MPH · PRINCIPAL_INVESTIGATOR · The SKCCC at Johns Hopkins

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologic proof or unequivocal cytologic proof solid tumor malignancy. This may be obtained from either the primary or any metastatic site
Mini Mental State Examination (MMSE) ≥24
Age≥ 18 years
Karnofsky Performance Status (KPS) ≥70
Patient does not have metastases to the genu
Patient must be scheduled to undergo treatment with whole brain radiation therapy (WBRT) to manage the brain metastases
Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child
Patient must have the ability to understand and the willingness to sign a written informed consent document
All patients must be informed of the investigational nature of this study and must be given written informed consent in accordance with institutional and federal guidelines
Patient must have a minimal life expectancy of at least 6 months
Patients receiving prior stereostatic radiosurgery (SRS) for brain metastases are eligible

Exclusion

Prior WBRT
MMSE\<24
Patient has brain metastases in the genu
Patients must not have a serious medical or psychiatric illness that would, in the opinion of the treating physician prevent informed consent or completion of protocol treatment, and/or follow-up visits.
KPS\<70
Non-native English speakers will be excluded since patients often lose their faculty with the language they acquired second before their native language is affected in the context of cognitive decline. This could adversely affect performance on verbal cognitive tasks.
Patients with absolute contraindication to MRI imaging are not eligible for the study

What this trial measures

  • Rate of change of cognitive function4 months

    Evaluate changes in cognition from baseline to 4 months following genu-sparing whole brain radiation therapy (GS-WBRT)